0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Alaunos Therapeutics Inc

Healthcare US TCRT

1.16USD
-0.02(1.69%)

Last update at 2024-04-25T20:00:00Z

Day Range

1.071.20
LowHigh

52 Week Range

0.040.86
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -37.73000M -78.75100M -79.97600M -117.79600M -53.11700M
Minority interest - - - - -
Net income -37.59700M -76.89400M -78.84800M -177.91800M -53.11700M
Selling general administrative 13.14M 27.56M 27.66M 19.53M 19.92M
Selling and marketing expenses - - - - -
Gross profit 2.92M -0.34200M - - 0.15M
Reconciled depreciation 2.76M 2.60M 1.13M 0.63M 0.57M
Ebit -35.10500M -77.54900M -81.48900M 2.26M -54.63900M
Ebitda -34.70900M -76.06900M -80.36100M 2.89M -54.06400M
Depreciation and amortization 0.40M 1.48M 1.13M 0.63M 0.57M
Non operating income net other 0.53M - - - -
Operating income -35.10500M -77.54900M -80.36100M 2.26M -53.90600M
Other operating expenses 38.16M 77.21M 80.36M 57.86M 54.05M
Interest expense 3.15M 1.18M 0.39M 120.69M 0.79M
Tax provision - - - - -
Interest income - - - - -
Net interest income -3.15400M -1.18200M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.13300M -1.85700M -1.12800M 60.12M -0.94700M
Total revenue 2.92M 0.40M 0.00000M 0.00000M 0.15M
Total operating expenses 38.16M 77.21M 80.36M 57.86M 54.05M
Cost of revenue - 0.74M - - -
Total other income expense net -2.62500M -1.20200M 0.39M -120.06000M 0.79M
Discontinued operations - - - - -
Net income from continuing ops -37.73000M -78.75100M -79.97600M -117.79600M -53.11700M
Net income applicable to common shares -37.73000M -78.75100M -79.97600M -117.79600M 137.25M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 64.94M 94.86M 146.34M 109.11M 95.05M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.80M 1.67M 10.86M 22.42M 20.69M
Total liab 26.38M 36.81M 22.36M 109.11M 9.49M
Total stockholder equity 38.55M 58.06M 123.98M 95.01M 85.56M
Deferred long term liab - - - - -
Other current liab 5.45M 6.08M 16.59M 10.85M 8.78M
Common stock 0.24M 0.22M 0.21M 0.18M 0.16M
Capital stock 0.24M 0.22M 0.21M 0.18M 0.16M
Retained earnings -880.62700M -842.85200M -764.10100M -684.12500M -566.32900M
Other liab 0.03M -0.00100M - - 0.00400M
Good will - - - - -
Other assets 0.54M 0.67M 0.88M 0.24M 9.67M
Cash 39.06M 76.05M 115.07M 79.74M 61.73M
Cash and equivalents - - - - -
Total current liabilities 24.17M 16.04M 18.37M 12.53M 9.48M
Current deferred revenue - - - - -
Net debt -19.54700M -46.68900M -110.25500M -77.38900M -61.72900M
Short term debt 17.32M 8.60M 0.82M 0.77M -
Short long term debt 16.77M 7.87M - - -
Short long term debt total 19.51M 29.36M 4.81M 2.35M -
Other stockholder equity 918.94M 900.69M 887.87M 778.95M 651.73M
Property plant equipment 8.46M 15.36M 14.88M 3.38M 1.10M
Total current assets 53.80M 78.83M 130.59M 105.49M 84.28M
Long term investments - - - - -
Net tangible assets 38.55M 58.06M 123.98M 95.01M 85.56M
Short term investments - - - - -
Net receivables 0.00400M 1.11M 4.67M 3.33M 1.86M
Long term debt - 16.25M - - -
Inventory 13.94M - - - -
Accounts payable 1.39M 1.37M 0.96M 0.91M 0.71M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity 0.24M - - - -
Preferred stock total equity - - - - -
Retained earnings total equity -880.62700M - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.54M 0.67M 0.88M 0.24M 9.67M
Deferred long term asset charges - - - - -
Non current assets total 11.14M 16.03M 15.76M 3.62M 10.77M
Capital lease obligations 2.75M 5.25M 4.81M 2.35M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.19300M -3.32300M -9.77800M -0.28400M -0.45900M
Change to liabilities -0.66500M 0.27M 0.05M 0.20M -3.85500M
Total cashflows from investing activities -0.19300M -3.32300M -9.77800M -0.28400M -0.45900M
Net borrowings -8.33300M 25.00M 25.00M 25.00M 25.00M
Total cash from financing activities 6.37M 25.78M 102.12M 59.15M 40.31M
Change to operating activities -2.14300M -1.04000M 16.29M 9.49M 1.41M
Net income -37.73000M -78.75100M -79.97600M -117.79600M -53.11700M
Change in cash -23.05800M -39.01500M 35.33M 18.01M -9.60500M
Begin period cash flow 76.05M 115.07M 79.74M 61.73M 71.33M
End period cash flow 53.00M 76.05M 115.07M 79.74M 61.73M
Total cash from operating activities -29.23200M -61.46800M -57.01300M -40.85400M -49.45700M
Issuance of capital stock 14.72M 0.00000M 101.68M 6.08M 47.10M
Depreciation 2.76M 2.60M 1.13M 0.63M 0.57M
Other cashflows from investing activities 0.02M - - - -
Dividends paid - - - - 17.00M
Change to inventory - -3.55500M - 1.47M 1.53M
Change to account receivables 1.11M 3.56M -1.33500M -1.46600M -1.84500M
Sale purchase of stock -0.04500M - 0.00000M -0.65300M -1.62200M
Other cashflows from financing activities 0.02M 25.78M 0.44M 53.72M 29.07M
Change to netincome 0.00700M 11.51M 6.83M 68.09M 7.38M
Capital expenditures 0.22M 3.32M 9.78M 0.28M 0.46M
Change receivables 1.11M - - - -
Cash flows other operating 4.31M - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -23.05800M - - - -
Change in working capital -1.06100M 2.79M 15.01M 8.22M -4.29100M
Stock based compensation 3.53M 10.77M 6.83M 7.34M 7.53M
Other non cash items 3.27M 0.38M -4.24900M 60.75M -0.15800M
Free cash flow -29.44800M -64.79100M -66.79100M -41.13800M -49.91600M

Fundamentals

  • Previous Close 1.18
  • Market Cap12.71M
  • Volume9252
  • P/E Ratio-
  • Dividend Yield1.36%
  • EBITDA-28.38600M
  • Revenue TTM0.01M
  • Revenue Per Share TTM-
  • Gross Profit TTM -19.59600M
  • Diluted EPS TTM-0.15

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TCRT
Alaunos Therapeutics Inc		 -0.02 1.69% 1.16 - - 842.19 0.91 123.99 -0.0602
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.

Alaunos Therapeutics Inc

8030 El Rio Street, Houston, TX, United States, 77054

Key Executives

Name Title Year Born
Mr. Kevin S. Boyle Sr. CEO & Director 1974
Mr. Michael Wong VP of Fin. & Principal Accounting Officer 1980
Mr. Abhishek Srivastava Ph.D. VP of Technical Operations NA
Ms. Melinda Lackey Sr. VP of Legal & Sec. 1977
Dr. Drew C. Deniger Ph.D. VP of R&D 1980

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).